Icagen IPO isn't prescription-strength.

• Position: TRIANGLE - Initial public offerings - Brief Article

Icagen landed about $37 million when it became the first Tar Heel company to go public since 2002, but it had hoped for more. The Durham drug developer cut its proposed IPO price from $12 to $8--and even that might have been too high. The stock crept to $8.06 before slipping to $7.30 by the end of the first trading day. Durham-based Red Hat closed its first day of...